RFA Plus Carrizumab vs Carrizumab Alone for HCC

The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS. 120 patients were enrolled into two groups respectively, the experimental group and reference group.

Inclusion criteria

• Age from 18-75 years
• Diagnosis as hepatocellular carcinoma from histology and cytology
• BCLC B-C degree
• Score of ECOG PS: 0-2
• Child-Pugh Score: A or B
• Not suitable for resection or liver transplantation
• Have not received systemic therapy
• Have at least one evaluable target mass from CT or MRI according to mRECIST
• The estimated survival time ≥ 12 weeks
• Patients with HBV infection having HBV-DNA <500IU/mL and standard anti-virus treatment. Patients with HCV infection must receive standard anti-virus treatment.
• The function of main organs normal
• Sign informed consent

Exclusion criteria

• Have cholangiocarcinoma, mixed type of hepatocarcinoma and fibrolamellar hepatocellular carcinoma. Have incurable malignant tumor in five years.
• Have local ablation, TACE or radiotherapy in 3 months before enrolled.
• Prepared to or have received organic or bone marrow transplantation.
• Uncontrollable ascites, hepatic encephalopathy or esophageal and gastric varices.
• Have hypertension and can't lower down to the normal level using blood pressure medication.
• Have type II myocardial ischemia or myocardial infarction, uncontrollable arrhythmia.
• Have diseases to influent the effect of oral drugs, for example, unable to swallow, chronic diarrhea and intestinal obstruction.
• Have gastrointestinal bleeding in 6 months
• Have abdominal fistula, gastrointestinal perforation or abdominal abscess
• Patients with lung fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug related pneumonia or severe dysfunction of lung.
• Routine urine test showed urinary protein ≥++ or the 24 hours amount of urinary protein ≥1.0 g
• Patients have autoimmune disease
• Patients need corticosteroid or other immunosuppressant therapy
• Patients have anti-tumor vaccine and other immunostimulate anti-tumor drugs in 3 months
• Allergy to monocloning antibody
• Pregnant or breastfeeding female Other patients not suitable to be enrolled in the study.